The Adherence Crisis Nobody in Psychiatry Talks About

Sixty percent of patients who start psychiatric medication drop off treatment within three months. Not because the medication does not work. Not because the patient gave up. Because the care model was not built to keep anyone in.

That number is not new. It has appeared in research for decades. It was cited in landmark STAR*D trial analyses, referenced in SAMHSA reports, and documented across dozens of prospective adherence studies. And yet the psychiatric care system has done almost nothing structurally to change it. The quarterly appointment model remains the default. The prescription is written. The patient goes home. And most of them, quietly, stop.

This is the adherence crisis. It does not make headlines. It does not generate the same urgency as access wait times or insurance coverage gaps. But it drives more treatment failure in mental health than almost any other clinical problem.

What the Data Actually Shows

The numbers are not ambiguous.

In the Medical Expenditure Panel Survey, researchers found that 42% of patients discontinued antidepressants within the first 30 days of treatment, and 72% had stopped within 90 days. These are not patients with severe treatment resistance or unusual circumstances. They are typical outpatients starting a first or second antidepressant prescription.

A broader dataset involving more than 740,000 patients given new SSRI prescriptions found that almost half failed to adhere to therapy for 60 days or more, and only 28% were compliant at 6 months.

Research on antidepressant adherence notes that approximately 30% of patients discontinue antidepressants within 1 month and up to 60% within 3 months, a pattern consistently associated with poor depression outcomes. Among psychiatric patients more broadly, approximately 65% of patients with severe mental illness do not adhere to their prescribed medication, with dropout and readmission as common downstream consequences.

Why Side Effects Win

The single most clinically predictable cause of early dropout is the timing asymmetry between side effects and benefits.

Almost every psychiatric medication produces side effects before it produces therapeutic effect. An SSRI starts affecting serotonin within hours. The nausea, insomnia, and activation that can accompany this arrive in the first days. The antidepressant effect, which depends on neuroadaptive changes that take weeks to complete, does not arrive until weeks four through eight.

A patient who starts sertraline at week one and experiences nausea, disrupted sleep, and an initial worsening of anxiety is not experiencing treatment failure. They are experiencing the adjustment phase. But without that clinical context being reinforced by someone checking in between appointments, the rational conclusion is that the medication is making things worse. Many patients stop before anyone knows they have.

Research on discontinuation found that experiencing one or more extremely bothersome side effects more than doubles the risk of discontinuation in patients with major depression, regardless of the specific SSRI prescribed. Weight change and anxiety were the strongest individual side effect predictors. Both are common, both typically emerge early, and both are manageable with clinical guidance that most patients do not have access to between quarterly visits.

The Care Model Creates the Problem

The adherence crisis is not a patient compliance problem. It is a structural design problem.

The quarterly appointment model was built around in-person logistics: scheduling, travel, insurance billing cycles. It was not designed around what patients with depression and anxiety actually need, which is contact at the moments when their treatment is most fragile, primarily in the first weeks on a new medication and in the months after initial symptom improvement.

Most patients who stop psychiatric medication are not making reckless decisions. They are making reasonable ones given what they know. Side effects feel worse than expected. No one is asking how they are doing. Feeling better, they conclude that medication is no longer necessary. More than three quarters of people believe that antidepressants are addictive, and most prefer psychotherapy or no treatment. When no one is available to address these beliefs between appointments, they go uncontested, and they drive dropout.

The care model does not fail patients by prescribing the wrong medication. It fails them by not following up. That is a different problem, and it has a different fix.

What Happens After Dropout

The clinical cost of dropout compounds over time.

For patients who stop antidepressants before the therapeutic window closes, the consequence is straightforward: they never experienced the medication’s benefit. They conclude it did not work. The next prescription starts the same cycle from a lower point of trust.

The STAR*D trial documented that remission rates decline significantly with each successive treatment step: approximately 37% in the first step, with substantially lower rates at each subsequent step. Every unnecessary discontinuation before an adequate trial raises the clinical complexity of the next attempt.

For patients who stop after achieving remission, the consequences are well-documented and serious. Among patients with major depression who relapsed versus those who maintained treatment, hospitalization rates were significantly higher (16.6% vs. 8.5%) and emergency department visits were substantially more common (54.8% vs. 34.7%). Relapse is not just a clinical setback. It increases the economic and human cost of a condition that was being successfully managed.

A study in NEJM found that among patients who felt well enough to consider stopping antidepressants, those who discontinued had a 56% relapse rate within 52 weeks, compared to 39% among those who continued treatment. Feeling better is not the same as being clinically stable enough to discontinue. Without ongoing monitoring, patients and prescribers often cannot tell the difference in time.

Why Nobody Talks About This

The adherence crisis is invisible in ways that other psychiatric problems are not.

Wait times are visible because they happen before care starts. There is a list, a date, a gap that is easy to measure. The adherence crisis happens after care starts, in the space between appointments. The patient who stopped their medication at week three does not show up in a statistic until they end up in an emergency room months later. The connection between the dropout and the outcome is rarely traced back.

There is also a framing problem. When patients discontinue treatment, the narrative defaults to patient factors: they did not follow through, they did not want help, they prioritized other things. The structural contribution, the care model that offered no follow-up in the weeks when they were most at risk, is rarely named as the primary contributor.

Psychiatric disorders are associated with a treatment gap that increases the burdens of patients, families, communities, and countries, according to global mental health research. That treatment gap is not only about access to a first appointment. It is about what happens, or what does not happen, after the prescription is written.

What the Evidence Supports

The solution the data consistently points toward is continuous monitoring, not more reminder apps or longer appointments.

A comprehensive integrative review of measurement-based care in psychiatry found that systematic tracking of patient progress produced increased remission rates, lower relapse risk, improved medication adherence, and stronger therapeutic alliance compared to usual care. When prescribers can see longitudinal data on symptom trajectory, side effect timing, and adherence patterns, they intervene earlier, with better information, and at the moments that actually matter clinically.

The intervention that prevents dropout is not more education at the first appointment. It is structured contact at weeks two through eight, when side effects are most prominent and patients are most likely to stop. That contact does not require a full appointment. It requires someone seeing what is happening and responding to it.

How SiggyMD Was Built Around This Problem

SiggyMD was built from the premise that the adherence crisis is structural, and that fixing it requires changing the structure, not changing the patient.

The anonymous AI intake removes the friction that prevents many people from starting treatment at all. Once a treatment plan is approved by a licensed prescriber, daily check-ins create the longitudinal clinical record that makes real-time monitoring possible. When a patient’s side effects are peaking at day five and starting to resolve by day ten, that trajectory is visible in the data before the next clinical decision point. When adherence has been inconsistent, the prescriber sees it before drawing conclusions about whether the medication is working.

The same data that captures side effects captures adherence. The prescriber reviewing a dose change is not working from a three-month recall summary. They are working from actual daily patterns. That changes the quality of every clinical decision downstream.

“The patients who drop off are almost always doing it in the first few weeks,” says Elizabeth Lokenauth, PA-C, of the SiggyMD clinical team. “They hit a side effect they were not prepared for, no one checks in, and they conclude the medication is not for them. If we are watching the data and reaching out when the pattern starts, we can change what happens next. Most of those patients would have stayed in treatment if someone had been there at the right moment.”

What Members Are Saying

CL

C.L., 33

Generalized Anxiety and Depression

“I stopped my first antidepressant at week two because the nausea was bad and I did not know it would get better. When I started with Siggy, the check-in data tracked the nausea declining over ten days. I could see it was improving before I felt it. I stayed with the medication. It started working by week six.”

MJ

M.J., 47

Major Depressive Disorder

“I felt better after three months and quietly stopped my medication. Six months later I was in the worst depressive episode of my life. My prescriber at Siggy explained that feeling better and being clinically stable enough to discontinue are not the same thing. I did not know that. Nobody had ever told me.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

The adherence crisis in psychiatry is not a patient problem. It is a structural one. The quarterly appointment model was never designed to catch what happens in the first weeks of treatment, when side effects arrive before benefits, when patients stop because no one is watching, and when the clinical cost of that dropout compounds into relapses that could have been prevented.

The fix is continuous monitoring: care that stays with the patient between visits, sees what is actually happening, and responds before dropout becomes inevitable. That is what SiggyMD was built to provide. Not a better app. A different care model.

Ready to start with a team that stays with you? Start your anonymous intake with SiggyMD and get a treatment plan reviewed by a real doctor, with daily check-ins that keep your care team informed between visits.

Sources

• Psychiatric Times. Understanding Medication Discontinuation in Depression. Accessed June 2026.

• Rossom RC, et al. Antidepressant Adherence Across Diverse Populations and Healthcare Settings. Depression and Anxiety. 2016;33(8):765-774.

• Goethe JW, et al. SSRI Discontinuation: Side Effects and Adherence. Journal of Clinical Psychopharmacology. 2007;27(5):451-458.

• Rush AJ, et al. Acute and Longer-Term Outcomes in Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry. 2006;163(11):1905-1917.

• Lewis G, et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. 2021;385:1257-1267.

• Touya M, et al. Incremental Burden of Relapse in Patients with Major Depressive Disorder. BMC Psychiatry. 2022;22(1).

• DeSimone J, Hansen BR. The Impact of Measurement-Based Care in Psychiatry. Journal of the American Psychiatric Nurses Association. 2023;30(2):279-287.

• Khan T, et al. Treatment Non-Adherence Patterns Among Patients With Mental Illness. Cureus. 2024.